FDA Approves Orserdu (elacestrant) for Patients with ESR1 Mutations in ER+, HER2- Advanced or Metastatic Breast Cancer
ESR1 mutations are present in up to 40% of ER+, HER2- advanced or metastatic breast cancers.
ESR1 mutations are a known driver of resistance to standard endocrine therapy, and so far, have been difficult to treat.
Orserdu is the first endocrine...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Drugs & Pharmacology | Endocrine Therapy | HER2